A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Eli Lilly and Company
Eli Lilly and Company
University of Pittsburgh
Genentech, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
Eli Lilly and Company
National Cancer Institute (NCI)
OncoC4, Inc.
Jazz Pharmaceuticals
Revolution Medicines, Inc.
Bayer
USWM, LLC (dba US WorldMeds)
Arcus Biosciences, Inc.
AstraZeneca
Imperial College London
SystImmune Inc.
Institut Paoli-Calmettes
Mayo Clinic
Sutro Biopharma, Inc.
Neonc Technologies, Inc.
ViroMissile, Inc.
Duke University
Qurient Co., Ltd.
Duke University
Essen Biotech
Revolution Medicines, Inc.
SystImmune Inc.
xCures
Daiichi Sankyo
University of Nebraska
Adela, Inc
Perspective Therapeutics
Second Life Therapeutics
Novartis
Tanabe Pharma America, Inc.
University Health Network, Toronto
NeoTX Therapeutics Ltd.
CRISPR Therapeutics
Laekna Limited
Tempus AI
Massive Bio, Inc.
Incyte Corporation
Actym Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Pfizer